Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) Overview | 14 | 1 |
| Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) Comparative Analysis | 15 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Development by Companies | 16 | 4 |
| Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Investigation by Universities/Institutes | 20 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Products Glance | 21 | 4 |
| Late Stage Products | 21 | 1 |
| Clinical Stage Products | 22 | 1 |
| Early Stage Products | 23 | 1 |
| Unknown Stage Products | 24 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Products under Development by Companies | 25 | 4 |
| Attention Deficit Hyperactivity Disorder (ADHD) Products under Investigation by Universities/Institutes | 29 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Companies Involved in Therapeutics Development | 30 | 36 |
| Alcobra Ltd | 30 | 1 |
| Amarantus Bioscience Holdings, Inc. | 31 | 1 |
| APeT Holding BV | 32 | 1 |
| Arbor Pharmaceuticals, LLC | 33 | 1 |
| BCWorld Pharm Co. Ltd. | 34 | 1 |
| BioLite, Inc. | 35 | 1 |
| Collegium Pharmaceutical, Inc. | 36 | 1 |
| Curemark, LLC | 37 | 1 |
| DURECT Corporation | 38 | 1 |
| Egalet Corporation | 39 | 1 |
| Eli Lilly and Company | 40 | 1 |
| Ensysce Biosciences Inc. | 41 | 1 |
| H. Lundbeck A/S | 42 | 1 |
| Heptares Therapeutics Limited | 43 | 1 |
| Highland Therapeutics, Inc. | 44 | 1 |
| Integrative Research Laboratories Sweden AB | 45 | 1 |
| Intra-Cellular Therapies, Inc. | 46 | 1 |
| INVENT Pharmaceuticals, Inc. | 47 | 1 |
| KemPharm, Inc. | 48 | 1 |
| Luc Therapeutics, Inc. | 49 | 1 |
| Medgenics, Inc. | 50 | 1 |
| Merck &Co., Inc. | 51 | 1 |
| Neos Therapeutics, Inc. | 52 | 1 |
| NeuroDerm Ltd. | 53 | 1 |
| Neurovance, Inc. | 54 | 1 |
| NLS Pharma Group | 55 | 1 |
| Noven Pharmaceuticals, Inc. | 56 | 1 |
| P2D Bioscience | 57 | 1 |
| Polleo Pharma Limited | 58 | 1 |
| Reviva Pharmaceuticals Inc. | 59 | 1 |
| Shire Plc | 60 | 1 |
| Sunovion Pharmaceuticals Inc. | 61 | 1 |
| Supernus Pharmaceuticals, Inc. | 62 | 1 |
| Taisho Pharmaceutical Co., Ltd. | 63 | 1 |
| Taisho Pharmaceutical Holdings Co., Ltd. | 64 | 1 |
| TRImaran Pharma, Inc. | 65 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Assessment | 66 | 12 |
| Assessment by Monotherapy Products | 66 | 1 |
| Assessment by Combination Products | 67 | 1 |
| Assessment by Target | 68 | 3 |
| Assessment by Mechanism of Action | 71 | 3 |
| Assessment by Route of Administration | 74 | 2 |
| Assessment by Molecule Type | 76 | 2 |
| Drug Profiles | 78 | 101 |
| (nicotine + opipramol hydrochloride) Drug Profile | 78 | 1 |
| AR-08 Drug Profile | 79 | 1 |
| BCWPE-003 Drug Profile | 80 | 1 |
| BLI-1008 Drug Profile | 81 | 1 |
| BNC-375 Drug Profile | 82 | 1 |
| CB-8411 Drug Profile | 83 | 1 |
| centanafadine IR Drug Profile | 84 | 1 |
| centanafadine SR Drug Profile | 85 | 3 |
| CM-4612 Drug Profile | 88 | 1 |
| CTX-1301 Drug Profile | 89 | 1 |
| CTX-1302 Drug Profile | 90 | 1 |
| dasotraline hydrochloride Drug Profile | 91 | 2 |
| dextroamphetamine Drug Profile | 93 | 1 |
| dextroamphetamine MR Drug Profile | 94 | 2 |
| edivoxetine hydrochloride Drug Profile | 96 | 2 |
| Egalet-003 Drug Profile | 98 | 1 |
| eltoprazine Drug Profile | 99 | 5 |
| etiguanfacine Drug Profile | 104 | 1 |
| fasoracetam Drug Profile | 105 | 2 |
| guanfacine hydrochloride ER Drug Profile | 107 | 2 |
| histamine dihydrochloride Drug Profile | 109 | 1 |
| HTL-1071 Drug Profile | 110 | 2 |
| INV-107 Drug Profile | 112 | 1 |
| INV-170 Drug Profile | 113 | 1 |
| IRL-752 Drug Profile | 114 | 1 |
| ITI-214 Drug Profile | 115 | 2 |
| KP-415 CR Drug Profile | 117 | 2 |
| lisdexamfetamine dimesylate Drug Profile | 119 | 7 |
| mazindol Drug Profile | 126 | 1 |
| Metadoxine ER Drug Profile | 127 | 7 |
| methylphenidate hydrochloride ER Drug Profile | 134 | 1 |
| methylphenidate hydrochloride MR Drug Profile | 135 | 4 |
| methylphenidate hydrochloride SR Drug Profile | 139 | 2 |
| methylphenidate hydrochloride XR Drug Profile | 141 | 2 |
| MGS-0028 Drug Profile | 143 | 1 |
| molindone hydrochloride ER Drug Profile | 144 | 2 |
| niacinamide CR Drug Profile | 146 | 1 |
| NLS-3 Drug Profile | 147 | 1 |
| NLS-4 Drug Profile | 148 | 1 |
| NT-0201 Drug Profile | 149 | 1 |
| P-001 Drug Profile | 150 | 1 |
| PBF-509 Drug Profile | 151 | 1 |
| PD-2005 Drug Profile | 152 | 1 |
| PD-3044 Drug Profile | 153 | 1 |
| PFR-08001 Drug Profile | 154 | 1 |
| PFR-8026 Drug Profile | 155 | 1 |
| RP-5063 Drug Profile | 156 | 2 |
| SHP-465 Drug Profile | 158 | 2 |
| Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder Drug Profile | 160 | 1 |
| Small Molecules for Attention Deficit Hyperactivity Disorder Drug Profile | 161 | 1 |
| Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder Drug Profile | 162 | 1 |
| Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder Drug Profile | 163 | 1 |
| Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders Drug Profile | 164 | 1 |
| Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders Drug Profile | 165 | 1 |
| Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD Drug Profile | 166 | 1 |
| Small Molecules to Modulate Choline Transporter for ADHD Drug Profile | 167 | 1 |
| Synthetic Peptide to Antagonize D2 for ADHD Drug Profile | 168 | 1 |
| TS-141 Drug Profile | 169 | 1 |
| Vaccine for CNS Disorders Drug Profile | 170 | 1 |
| viloxazine hydrochloride ER Drug Profile | 171 | 1 |
| vortioxetine hydrobromide Drug Profile | 172 | 6 |
| VU-0238429 Drug Profile | 178 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects | 179 | 5 |
| Attention Deficit Hyperactivity Disorder (ADHD) Discontinued Products | 184 | 1 |
| Attention Deficit Hyperactivity Disorder (ADHD) Product Development Milestones | 185 | 12 |
| Featured News &Press Releases | 185 | 1 |
| Jul 27, 2016: Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials | 185 | 1 |
| Jul 14, 2016: KemPharm Completes Key Regulatory Meeting with FDA for KP415 | 186 | 1 |
| Jun 29, 2016: Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults with ADHD | 186 | 1 |
| Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD | 187 | 1 |
| Jun 16, 2016: FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD | 188 | 1 |
| Jun 06, 2016: Highland Therapeutics Announces Positive Data from Second Pivotal ADHD Trial For HLD-200 | 188 | 1 |
| May 12, 2016: NLS Pharma Announces Submission of Investigational New Drug Application to FDA for Its Controlled-Release Mazindol for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder | 189 | 1 |
| Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets | 190 | 1 |
| Apr 05, 2016: Highland Therapeutics Announces Positive Pivotal ADHD Trial Results for Its Investigational Drug Candidate Benjorna | 190 | 2 |
| Apr 04, 2016: Shire Announces Positive Results of SHP465 Safety and Efficacy Study in Children and Adolescents with ADHD | 192 | 1 |
| Mar 30, 2016: Highland Therapeutics Announces Trade Name Benjorna for Its Next-Generation ADHD Medicine | 193 | 1 |
| Mar 04, 2016: Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board | 193 | 1 |
| Feb 10, 2016: Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children | 194 | 1 |
| Jan 27, 2016: Submission of Manufacturing and Marketing Authorization Application for ADHD Medicine S - 877503 | 195 | 1 |
| Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline | 196 | 1 |
| Appendix | 197 | 2 |
| Methodology | 197 | 1 |
| Coverage | 197 | 1 |
| Secondary Research | 197 | 1 |
| Primary Research | 197 | 1 |
| Expert Panel Validation | 197 | 1 |
| Contact Us | 197 | 1 |
| Disclaimer | 198 | 1 |